Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 6/20 | 0.39 |
| ▸ | FLT4 | P35916 | 6/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469215 | 0.99 | KDR (0.41) | KDREGFRRETFLT1FLT4 | |
| SCHEMBL6468687 | 0.96 | EHMT2 (0.43) | KDRFLT1FLT4EHMT2EHMT1 | |
| SCHEMBL6467496 | 0.95 | AVPR1B (0.41) | KDREGFRRETFLT1FLT4 | |
| SCHEMBL6470132 | 0.94 | PDK1 (0.39) | RETAVPR1BRAF1 | |
| SCHEMBL6469285 | 0.92 | HRH3 (0.36) | EGFRRETEHMT2CSF1RHRH3 | |
| SCHEMBL6470906 | 0.90 | HRH3 (0.39) | KDRHRH3AVPR1B | |
| SCHEMBL6467103 | 0.90 | RAF1 (0.38) | EGFRRETEHMT2CSF1RHRH3 | |
| SCHEMBL6469454 | 0.90 | FGFR4 (0.38) | KDREGFRRETFLT1FLT4 | |
| SCHEMBL6469963 | 0.89 | MEN1 (0.41) | RAF1 | |
| SCHEMBL6469208 | 0.89 | TDP2 (0.35) | RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | KDR 4703/4885EGFR 4458/4885RET 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.